Purdue Institute for Drug Discovery

HL-07

Overview: 

Imatinib repurposing for malaria treatment

Status: 

Purdue Faculty: 

Dr. Philip Low

Clinical Trial Information: 

Phase 2 Trial - Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites (Artesynib)

Phase 1 Trial - Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria (MIM)

Research Articles: 

Imatinib augments standard malaria combination therapy without added toxicity

Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia